Reversing Immune Aging to Improve Immunotherapy Outcomes
Abstract
Age-related immune decline may limit cancer immunotherapy effectiveness, particularly in patients ages 75 and older. Researchers are exploring mRNA-based immune rejuvenation and senolytics as potential solutions, with a growing number of human trials now testing whether targeting immune aging can improve treatment response. Translating these findings more broadly will require addressing safety concerns and the complexity of human immune aging.
Fields of Study & Subjects
Cancer Immunotherapy and Biomarkers
Immunotherapy and Immune Responses
Telomeres
Telomerase
and Senescence
Publication details
- Journal / source
- Cancer Discovery
- Volume
- 16
- Issue
- 4
- Pages
- OF1–OF1
- Publication date
- 24 February 2026
- Language
- EN